Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Enrollment opens in phase II study of AL-208 for CABG-associated MCI

June 9, 2006

Data from trial of eszopiclone in insomniac patients with depression further analyzed

June 9, 2006

PF-670462: new potent CKIe inhibitor evokes phase delays

June 9, 2006

Progesterone may be of benefit in treating brain trauma

June 9, 2006

Betaferon approved in Europe as first-line treatment for earliest stages of MS

June 8, 2006

Abilify launched in Japan

June 8, 2006

AZ-001 studied in phase IIb trial for migraine

June 8, 2006

Stimulant medications most effective in treating attention deficit hyperactivity disorder

June 8, 2006

Phase III results of lisdexamfetamine in ADHD presented

June 8, 2006

The CCR1 antagonist BX-471 evaluated in phase II clinical trials

June 7, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...